Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
308 participants
INTERVENTIONAL
2025-01-01
2029-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will:
* Either take
1. JAK inhibitor dose-tapering strategy.
2. JAK inhibitor continuous therapy strategy.
* Visit the clinic once every 3 months for checkups and tests
* Keep a diary of their treatment intake and symptoms
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.
NCT00754559
TOward the Lowest Effective DOse of Abatacept or Tocilizumab
NCT01557374
Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis
NCT05115903
A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day
NCT04267380
To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks
NCT05606107
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is recommended to target remission when initiating a DMARD and to assess patients according to a treat-to-target approach in order to adapt therapy. Once sustained remission is achieved, a decrease in the targeted therapeutic DMARD dose should be considered, according to the recommendations, in order to reduce the risk of adverse events and medical costs. Indeed, targeted DMARDs have considerably increased medical costs linked to RA and studies assessing medical economic impact of bDMARD down-titration on medical costs highlighted the cost-utility of such strategies.
JAK inhibitors, a novel class of targeted therapies have proved to be very effective in treating inflammation and preventing structural progression in RA. However, awareness has recently been raised regarding the safety of JAK inhibitor in the treatment of RA, with particular emphasis on tofacitinib. Indeed, tofacitinib seems to increase the risk of thromboembolism events, infections, neoplasia and major cardiovascular events in comparison to anti-TNF in RA, with a dose-effect.
To date, we have very little data regarding the feasibility of a JAK inhibitor dose-tapering strategy. As a dose-related effect was apparent in terms of major adverse events, we assume that JAK inhibitor dose-tapering strategy might reduce the risk of serious adverse events, without increasing the risk of major flares and thus be beneficial for the patient.
The aim of the study will be to compare a dose-tapering strategy versus therapy continuation in rheumatoid arthritis patients in low disease activity treated with JAK inhibitors on the risk of losing low disease activity despite rescue therapy at 12 months.
1\) The dose-tapering strategy will depend on the JAK inhibitor taken by the patient. It will be based on a 50% dose-reduction every 6 months and will comprise 2 steps:
A. Treatment with baricitinib 4 mg daily:
* Step 1 (after randomization): baricitinib 2mg daily.
* Step 2 (in case of CDAI ≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day.
B. Treatment with filgotinib 200 mg daily:
* Step 1 (after randomisation): filgotinib 100 mg daily.
* Step 2 (in case of CDAI ≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day.
C. Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily:
* Step 1 (after randomisation): tofacitinib 5 mg once daily.
* Step 2 (in case of CDAI ≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day.
D. Treatment with upadacitinib 15 mg daily:
* Step 1 (after randomisation): upadacitinib 15 mg every other day.
* Step 2 (in case of CDAI ≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): upadacitinib 15 mg every 4 days.
Management of flares:
1. In case of flare, diagnosed during a scheduled visit: the management of the flare will be standardized by a rescue therapy including a glucocorticoid course and returning to the previous step of JAK inhibitor dose. If the flare is not resolved after the rescue therapy, the patient will be considered in failure of the strategy.
2. In case of flare between two scheduled visits, an additional visit will be scheduled by the clinical center to confirm the flare by the physician. If the flare is confirmed, the patient will have the standardized flare management as described above.
2\) Patients randomised to the control group will have to continue the JAK inhibitor at full dose until the end of the protocol:
* In case of baricitinib: baricitinib 4mg/day.
* In case of filgotinib: filgotinib 200mg/day.
* In case of tofacitinib: tofacitinib 5mg twice daily or 11mg/day.
* In case of upadacitinib: upadacitinib 15mg/day.
Management of flares:
1. In case of flare, diagnosed during a scheduled visit: the management of the flare will be standardized by a rescue therapy with a glucocorticoid course. If the flare is not resolved after the rescue therapy, the patient will be considered in failure of the strategy.
2. In case of flare between two scheduled visits, an additional visit will be scheduled by the clinical center to confirm the flare by the physician. If the flare is confirmed, the patient will have the standardized flare management as described above.
Patients with co-medication with sDMARD or glucocorticoids \< 5mg/d will have to keep a stable dose of their treatment during the 12 months of the study in both groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
1. JAK inhibitor dose-tapering strategy.
2. JAK inhibitor continuous therapy strategy.
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JAK inhibitor dose-tapering strategy
The dose-tapering strategy will depend on the JAK inhibitor taken by the patient. It will be based on a 50% dose-reduction every 6 months and will comprise 2 steps:
A. Treatment with baricitinib 4 mg daily:
* Step 1 (after randomization): baricitinib 2mg daily.
* Step 2 (in case of CDAI ≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day.
B. Treatment with filgotinib 200 mg daily:
* Step 1 (after randomisation): filgotinib 100 mg daily.
* Step 2 (in case of CDAI ≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day.
C. Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily:
* Step 1 (after randomisation): tofacitinib 5 mg once daily.
* Step 2 (in case of CDAI ≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day.
D. Treatment with upadacitinib 15 mg daily:
• Step 1 (after randomisat
Baricitinib (LY3009104) 4 mg
Treatment with baricitinib 4 mg daily
* Step 1 (after randomization): baricitinib 2mg daily
* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day
filgotinib 200mg/day
Treatment with filgotinib 200 mg daily
* Step 1 (after randomisation): filgotinib 100 mg daily
* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day
Tofacitinib 5 mg twice daily
Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily
* Step 1 (after randomisation): tofacitinib 5 mg once daily
* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day
Upadacitinib 15 MG
Treatment with upadacitinib 15 mg daily
* Step 1 (after randomisation): upadacitinib 15 mg every other day
* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): upadacitinib 15 mg every 4 days
JAK inhibitor continuous therapy strategy
Full dose will be considered in patient taking:
* Baricitinib 4mg/day
* Filgotinib: 200mg/day
* Tofacitinib : 5mg twice daily or 11mg/day
* Upadacitinib: 15mg/day
Baricitinib (LY3009104) 4 mg
use of JAK inhibitor at full dose until the end of the protocol
filgotinib 200mg/day
use of JAK inhibitor at full dose until the end of the protocol
Tofacitinib 5 mg twice daily
use of JAK inhibitor at full dose until the end of the protocol
Upadacitinib 15 MG
use of JAK inhibitor at full dose until the end of the protocol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Baricitinib (LY3009104) 4 mg
Treatment with baricitinib 4 mg daily
* Step 1 (after randomization): baricitinib 2mg daily
* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day
filgotinib 200mg/day
Treatment with filgotinib 200 mg daily
* Step 1 (after randomisation): filgotinib 100 mg daily
* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day
Tofacitinib 5 mg twice daily
Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily
* Step 1 (after randomisation): tofacitinib 5 mg once daily
* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day
Upadacitinib 15 MG
Treatment with upadacitinib 15 mg daily
* Step 1 (after randomisation): upadacitinib 15 mg every other day
* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): upadacitinib 15 mg every 4 days
Baricitinib (LY3009104) 4 mg
use of JAK inhibitor at full dose until the end of the protocol
filgotinib 200mg/day
use of JAK inhibitor at full dose until the end of the protocol
Tofacitinib 5 mg twice daily
use of JAK inhibitor at full dose until the end of the protocol
Upadacitinib 15 MG
use of JAK inhibitor at full dose until the end of the protocol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Rheumatoid arthritis defined by the ACR/EULAR criteria.
3. Treated with a JAK inhibitor, full dose for at least 6 months.
4. The JAK inhibitor is prescribed as monotherapy or combined with a csDMARD with a stable dosage for at least 3 months before inclusion.
5. Being in LDA (CDAI≤10) for at least 6 months.
6. With a CRP level below the laboratory standard within the month before the inclusion visit.
7. Women of childbearing potential (WCBP) must have a negative pregnancy test before starting study
1. Concomitant disease needing to be treated by the JAK inhibitor at full-dose (for example inflammatory bowel disease).
2. Patient with a history of JAK-inhibitor dose reduction/spacing before enrollment in the study with the JAK-inhibitor currently being taken.
3. Evidence of flare-up within the last 6 months prior to the inclusion.
4. Patient who received glucocorticoids \> 5mg/day in the 3 months prior the inclusion because of the disease activity of the RA.
5. Patient requiring corticoid joint injections in the 3 months prior to inclusion or with scheduled joint injections, to control disease activity.
6. Patient at risk for complication according to the ANSM (60) (current or past smokers, patients at risk of VTE, cancer or major cardiovascular problems, aged ≥ 65 years) at baseline AND currently taking baricitinib or filgotinib.
7. Patient taking associated bDMARD (including anti-TNF, anti-IL6, anti-CD20, abatacept, anti-IL17, anti-IL12/23, anti-IL23, anti-IL1, anti-BAFF, anti-IL5 pathways).
8. Patient taking immunotherapy for neoplasia.
9. Surgery scheduled in the next 12 months.
10. Fibromyalgia according to the physician's opinion.
11. Anticipated poor compliance with the strategy.
12. Patient with any condition that would prevent participation in the study and completion of the study procedures, including language limitation.
13. Alcohol and/or drug misuse as determined by the investigator.
14. Pregnancy or breastfeeding.
15. Non-affiliation to the French Social Security System.
16. Patient unwilling to sign the informed consent form.
17. Patient under legal protection.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Toulouse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509788-25-00
Identifier Type: CTIS
Identifier Source: secondary_id
RC31/23/0373
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.